Cargando…

A Reduced Dose Whole Virion Aluminum Adjuvanted Seasonal Influenza Vaccine Is Immunogenic, Safe, and Well Tolerated in Pediatric Patients †

Background: Data suggest that pediatric patients might react differently to influenza vaccination, both in terms of immunity and side effects. We have recently shown that using a whole virion vaccine with aluminum phosphate adjuvants, reduced dose vaccines containing 6 µg of viral hemagglutinin (HA)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vajo, Zoltan, Balaton, Gergely, Vajo, Peter, Torzsa, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003037/ https://www.ncbi.nlm.nih.gov/pubmed/33803680 http://dx.doi.org/10.3390/v13030500

Ejemplares similares

Extinction of the Influenza B Yamagata Line during the COVID Pandemic—Implications for Vaccine Composition
por: Vajo, Zoltan, et al.
Publicado: (2022)

Developing Immunity Testing for SARS-CoV-2 and Other Novel Vaccines—Correlates of Immunogenicity Parameters with Protection
por: Vajo, Zoltan
Publicado: (2022)

Inactivated Whole Virus Influenza A (H5N1) Vaccine
por: Vajo, Zoltan, et al.
Publicado: (2007)

Yearly licensing studies from 1997 to 2007 of the inactivated whole virus seasonal influenza vaccine fluval – a useful approach to pandemic vaccine development even in less well developed countries?
por: Vajo, Zoltan, et al.
Publicado: (2008)

Immunogenicity and Tolerability after Two Doses of Non-Adjuvanted, Whole-Virion Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Individuals
por: Lagler, Heimo, et al.
Publicado: (2012)

Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination
por: Tavukcuoglu, Ece, et al.
Publicado: (2023)

Protection of Chinese painted quails (Coturnix chinensis) against a highly pathogenic H5N1 avian influenza virus strain after vaccination
por: Sarkadi, Julia, et al.
Publicado: (2013)

H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on Study
por: Walker, Woolf T., et al.
Publicado: (2012)

Safety and immunogenicity of AS03(B) adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study
por: Waddington, Claire S, et al.
Publicado: (2010)

Preclinical immunogenicity assessment of a cell-based inactivated whole-virion H5N1 influenza vaccine
por: Zhang, Zhegang, et al.
Publicado: (2022)

Long-Term Immunogenicity Studies of Formalin-Inactivated Enterovirus 71 Whole-Virion Vaccine in Macaques
por: Liu, Chia-Chyi, et al.
Publicado: (2014)

Long-term follow-up in patients with HIV vaccinated with pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine and seasonal trivalent influenza split virion vaccine
por: Pauksens, Karlis
Publicado: (2013)

Low immunogenicity of whole virion, verocell-derived, inactivated, pandemic influenza H1N1 vaccine in HIV-infected patients
por: Lagler, H, et al.
Publicado: (2010)

Evaluation of Thimerosal Removal on Immunogenicity of Aluminum Salts Adjuvanted Recombinant Hepatitis B Vaccine
por: Mahboubi, Arash, et al.
Publicado: (2012)

Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial
por: Rümke, Hans C, et al.
Publicado: (2013)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older
por: Schwarz, Tino F, et al.
Publicado: (2017)

Enhanced Immunogenicity, Mortality Protection, and Reduced Viral Brain Invasion by Alum Adjuvant with an H5N1 Split-Virion Vaccine in the Ferret
por: Layton, Robert Colby, et al.
Publicado: (2011)

Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults
por: Li, Athena P. Y., et al.
Publicado: (2021)

Aluminum Adjuvants—‘Back to the Future’
por: Laera, Donatello, et al.
Publicado: (2023)

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
por: Mohandas, Sreelekshmy, et al.
Publicado: (2021)

Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18–60 and 60+ Age Cohorts
por: Gordeychuk, Ilya V., et al.
Publicado: (2023)

Expression of FMD virus-like particles in yeast Hansenula polymorpha and immunogenicity of combine with CpG and aluminum adjuvant
por: Zhang, Jianhui, et al.
Publicado: (2023)

Native Morphology of Influenza Virions
por: Noda, Takeshi
Publicado: (2012)

Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India
por: Agarkhedkar, Sharad, et al.
Publicado: (2019)

Safety and tolerability of a 2009 trivalent inactivated split‐virion influenza vaccine in infants, children and adolescents
por: Lambert, Stephen B., et al.
Publicado: (2013)

Ternary metal fluorides as high-energy cathodes with low cycling hysteresis
por: Wang, Feng, et al.
Publicado: (2015)

A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice
por: Nachbagauer, Raffael, et al.
Publicado: (2016)

Aluminum exclusion and aluminum tolerance in woody plants
por: Brunner, Ivano, et al.
Publicado: (2013)

An increase in glycoprotein concentration on extracellular virions dramatically alters vaccinia virus infectivity and pathogenesis without impacting immunogenicity
por: Monticelli, Stephanie R., et al.
Publicado: (2021)

The Murine Gammaherpesvirus-68 gp150 Acts as an Immunogenic Decoy to Limit Virion Neutralization
por: Gillet, Laurent, et al.
Publicado: (2007)

Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes
por: Powell, Bradford S., et al.
Publicado: (2015)

Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60 years of age in the Republic of Korea
por: Choi, Won Suk, et al.
Publicado: (2017)

Mechanism of Immunopotentiation and Safety of Aluminum Adjuvants
por: HogenEsch, Harm
Publicado: (2013)

Oral intake of mesoporous silica is safe and well tolerated in male humans
por: Hagman, Emilia, et al.
Publicado: (2020)

A phase 2/3 double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a seasonal trivalent inactivated split-virion influenza vaccine (IVACFLU-S) in healthy adults in Vietnam
por: Lan, Phan Trong, et al.
Publicado: (2019)

Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine
por: Montalban, Cecilia, et al.
Publicado: (2017)

Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis
por: Lin, Yu-Ju, et al.
Publicado: (2018)

Biopersistence and Brain Translocation of Aluminum Adjuvants of Vaccines
por: Gherardi, Romain Kroum, et al.
Publicado: (2015)

Distinctive cellular response to aluminum based adjuvants
por: Nies, Isaac, et al.
Publicado: (2020)

Modulation of Skin Inflammatory Responses by Aluminum Adjuvant
por: Liao, Yanhang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dglfpbp5o5uj9i9r7m3rmujdpf